爱美客：全资子公司取得药品注册证书

Group 1 - Aimeike's subsidiary, Beijing Nobot Biotechnology Co., Ltd., received approval from the National Medical Products Administration for Minoxidil topical solution with specifications of 2% and 5% [1] - For the year 2024, Aimeike's revenue composition is projected to be 99.9% from the medical device industry and 0.1% from other industries [1] - Aimeike's market capitalization is currently valued at 55.1 billion yuan [1] Group 2 - The competition between Nongfu Spring and Yibao has intensified, with Nongfu Spring's green bottle launch leading to a significant market share decline for Yibao, dropping nearly 5 percentage points [1]